journal article·2023-11Open access

The Lipid Metabolism as Target and Modulator of BOLD‐100 Anticancer Activity: Crosstalk with Histone Acetylation

Dina Baier, Theresa Mendrina, Beatrix Schoenhacker‐Alte, Christine Pirker, Thomas Mohr, Mate Rusz, Benedict Regner, Martin Schaier, Nicolas Sgarioto, Noël J.‐M. Raynal, Karin Nowikovsky, Wolfgang M. Schmidt, Petra Heffeter, Samuel M. Meier‐Menches, Gunda Koellensperger, Bernhard K. Keppler, Walter Berger

Advanced Science· Volume 10· Issue 32

Abstract

Abstract The leading first‐in‐class ruthenium‐complex BOLD‐100 currently undergoes clinical phase‐II anticancer evaluation. Recently, BOLD‐100 is identified as anti‐Warburg compound. The present study shows that also deregulated lipid metabolism parameters characterize acquired BOLD‐100‐resistant colon and pancreatic carcinoma cells. Acute BOLD‐100 treatment reduces lipid droplet contents of BOLD‐100‐sensitive but not ‐resistant cells. Despite enhanced glycolysis fueling lipid accumulation, BOLD‐100‐resistant cells reveal diminished lactate secretion based on monocarboxylate transporter 1 (MCT1) loss mediated by a frame‐shift mutation in the MCT1 chaperone basigin. Glycolysis and lipid catabolism converge in the production of protein/histone acetylation substrate acetyl‐coenzymeA (CoA). Mass spectrometric and nuclear magnetic resonance analyses uncover spontaneous cell‐free BOLD‐100‐CoA adduct formation suggesting acetyl‐CoA depletion as mechanism bridging BOLD‐100‐induced lipid metabolism alterations and histone acetylation‐mediated gene expression deregulation. Indeed, BOLD‐100 treatment decreases histone acetylation selectively in sensitive cells. Pharmacological targeting confirms histone de‐acetylation as central mode‐of‐action of BOLD‐100 and metabolic programs stabilizing histone acetylation as relevant Achilles’ heel of acquired BOLD‐100‐resistant cell and xenograft models. Accordingly, histone gene expression changes also predict intrinsic BOLD‐100 responsiveness. Summarizing, BOLD‐100 is identified as epigenetically active substance acting via targeting several onco‐metabolic pathways. Identification of the lipid metabolism as driver of acquired BOLD‐100 resistance opens novel strategies to tackle therapy failure.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA modifications and cancer · RNA Research and Splicing · Cancer-related gene regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Cancer Research and Comprehensive Cancer Center Medical University Vienna Borschkegasse 8a Vienna 1090 Austria

Institute of Inorganic Chemistry University of Vienna Waehringer Str. 42 Vienna 1090 Austria

Research Cluster “Translational Cancer Therapy Research” Vienna 1090 Austria

Joint Metabolome Facility University of Vienna and Medical University of Vienna Waehringer Str. 38 Vienna 1090 Austria

ScienceConsult Guntramsdorf 2351 Austria

Institute of Analytical Chemistry Faculty of Chemistry University of Vienna Waehringer Str. 38 Vienna 1090 Austria

Anna Spiegel Center of Translational Research Department of Medicine I Medical University Vienna Lazarettgasse 14 Vienna 1090 Austria

Départment de pharmacologie et physiologie Faculté de médecine Centre de recherché de l hôpital Université de Montréal Saint‐Justine (7.17.020), 3175 Chemin de la Côte Ste‐Catherine Quebec H3T1C5 Canada

Unit of Physiology and Biophysics Department of Biomedical Sciences University of Veterinary Medicine Vienna Veterinaerplatz 1 Vienna 1210 Austria

Neuromuscular Research Department Center for Anatomy and Cell Biology Medical University of Vienna Währinger Str. 13 Vienna 1090 Austria

Funding

Fondation Charles-Bruneau · Fonds de Recherche du Québec - Santé · Austrian Science Fund

References (89)

Show source-provided references
1. 10.1016/j.canlet.2017.07.00910.1016/j.canlet.2017.07.009 ↗
2. 10.3390/cancers1209264710.3390/cancers12092647 ↗
3. 10.18632/oncotarget.2567910.18632/oncotarget.25679 ↗
4. 10.1016/j.neo.2016.09.00110.1016/j.neo.2016.09.001 ↗
5. 10.1158/1535-7163.MCT-15-077410.1158/1535-7163.MCT-15-0774 ↗
6. 10.1016/j.ejca.2013.05.01810.1016/j.ejca.2013.05.018 ↗
7. 10.1136/esmoopen-2016-00015410.1136/esmoopen-2016-000154 ↗
8. 10.1186/s12935-018-0538-710.1186/s12935-018-0538-7 ↗
9. 10.1186/s12935-015-0221-110.1186/s12935-015-0221-1 ↗
10. 10.1038/nrc.2016.7710.1038/nrc.2016.77 ↗
11. 10.1038/nrc.2016.7110.1038/nrc.2016.71 ↗
12. 10.3390/cells904082810.3390/cells9040828 ↗
13. 10.1096/fj.201601248R10.1096/fj.201601248R ↗
14. 10.2174/15680091179432850110.2174/156800911794328501 ↗
15. 10.1007/s00775-012-0944-610.1007/s00775-012-0944-6 ↗
16. 10.1007/s10637-016-0337-810.1007/s10637-016-0337-8 ↗
17. Pötsch I. · The Royal Society of Chemistry · 2019 · 308
18. 10.1002/anie.20201596210.1002/anie.202015962 ↗
19. Hendershot L. M. · Mt Sinai J Med · 2004 · 71 · 289
20. 10.21769/BioProtoc.191210.21769/BioProtoc.1912 ↗
21. 10.1146/annurev-biochem-061009-10243010.1146/annurev-biochem-061009-102430 ↗
22. 10.1016/j.ceb.2014.03.00810.1016/j.ceb.2014.03.008 ↗
23. 10.1126/science.110074710.1126/science.1100747 ↗
24. 10.1016/j.neuropharm.2011.08.04810.1016/j.neuropharm.2011.08.048 ↗
25. 10.1016/j.toxlet.2012.06.00210.1016/j.toxlet.2012.06.002 ↗
26. 10.1172/JCI3700710.1172/JCI37007 ↗
27. 10.1016/S0021-9258(18)69581-X10.1016/S0021-9258(18)69581-X ↗
28. 10.1158/0008-5472.CAN-09-387110.1158/0008-5472.CAN-09-3871 ↗
29. 10.1007/s10495-017-1366-210.1007/s10495-017-1366-2 ↗
30. 10.1186/s40880-018-0317-910.1186/s40880-018-0317-9 ↗
31. 10.1186/s12967-015-0511-310.1186/s12967-015-0511-3 ↗
32. 10.3390/cancers1316413010.3390/cancers13164130 ↗
33. 10.3390/pharmaceutics1402023810.3390/pharmaceutics14020238 ↗
34. 10.1038/s41580-021-00441-y10.1038/s41580-021-00441-y ↗
35. 10.21037/atm.2019.11.14010.21037/atm.2019.11.140 ↗
36. 10.1172/jci.insight.14246410.1172/jci.insight.142464 ↗
37. 10.1167/iovs.02-055210.1167/iovs.02-0552 ↗
38. 10.1074/jbc.M41195020010.1074/jbc.M411950200 ↗
39. 10.1073/pnas.050441910210.1073/pnas.0504419102 ↗
40. 10.1158/0008-5472.CAN-06-318410.1158/0008-5472.CAN-06-3184 ↗
41. 10.1016/j.ceb.2015.02.00310.1016/j.ceb.2015.02.003 ↗
42. 10.1146/annurev.bi.49.070180.00214310.1146/annurev.bi.49.070180.002143 ↗
43. 10.1016/j.cmet.2015.05.01410.1016/j.cmet.2015.05.014 ↗
44. 10.2174/138920002333705410.2174/1389200023337054 ↗
45. 10.1021/bi702438610.1021/bi7024386 ↗
46. 10.3390/ijms2119725410.3390/ijms21197254 ↗
47. 10.1194/jlr.M700050-JLR20010.1194/jlr.M700050-JLR200 ↗
48. 10.1016/0005-2760(87)90088-910.1016/0005-2760(87)90088-9 ↗
49. 10.1016/S0940-2993(00)80107-410.1016/S0940-2993(00)80107-4 ↗
50. 10.1158/0008-5472.CAN-03-364510.1158/0008-5472.CAN-03-3645 ↗
51. J.Zou S.Ganji I.Pass R.Ardecky M.Peddibhotla M.Loribelle S.Heynen‐Genel M.Sauer I.Pass S.Vasile E.Suyama S.Malany A.Mangravita‐Novo M.Vicchiarelli D.McAnally A.Cheltsov S.Derek S.Shi Y.Su F. Y.Zeng A. B.Pinkerton L. H.Smith S.Kim H.Ngyuen F. Y.Zeng J.Diwan A. J.Heisel R.Coleman P. M.McDonough T. D. Y.Chung inProbe Reports from the NIH Molecular Libraries Program Bethesda (MD) 2010.
52. 10.1002/ijc.3292410.1002/ijc.32924 ↗
53. 10.1021/jm960674d10.1021/jm960674d ↗
54. 10.1097/00005344-200012000-0001610.1097/00005344-200012000-00016 ↗
55. 10.1016/0026-0495(91)90214-H10.1016/0026-0495(91)90214-H ↗
56. 10.1016/j.lfs.2019.03.04410.1016/j.lfs.2019.03.044 ↗
57. 10.1080/0968786060084196710.1080/09687860600841967 ↗
58. 10.1016/j.cmet.2018.06.00110.1016/j.cmet.2018.06.001 ↗
59. 10.18632/oncotarget.2188710.18632/oncotarget.21887 ↗
60. 10.3389/fcell.2021.67244710.3389/fcell.2021.672447 ↗
61. 10.1038/sj.bjc.660346310.1038/sj.bjc.6603463 ↗
62. 10.1038/s41586-018-0387-510.1038/s41586-018-0387-5 ↗
63. 10.18632/oncotarget.2141610.18632/oncotarget.21416 ↗
64. Liang W. · Oxid Med Cell Longev · 2021 · 202110.1155/2021/5537737 ↗
65. 10.1002/jcp.2240010.1002/jcp.22400 ↗
66. 10.4161/cc.8.23.1023810.4161/cc.8.23.10238 ↗
67. 10.1038/sj.bjc.660026410.1038/sj.bjc.6600264 ↗
68. 10.1136/gut.2009.18141210.1136/gut.2009.181412 ↗
69. 10.1091/mbc.e12-06-042810.1091/mbc.e12-06-0428 ↗
70. 10.1093/emboj/19.15.389610.1093/emboj/19.15.3896 ↗
71. 10.1038/s41392-022-01151-310.1038/s41392-022-01151-3 ↗
72. 10.1039/c9mt00051h10.1039/c9mt00051h ↗
73. 10.1016/j.febslet.2014.02.01710.1016/j.febslet.2014.02.017 ↗
74. 10.1093/nar/gkz86410.1093/nar/gkz864 ↗
75. 10.1158/1535-7163.MCT-09-098810.1158/1535-7163.MCT-09-0988 ↗
76. 10.1158/0008-5472.CAN-09-194710.1158/0008-5472.CAN-09-1947 ↗
77. 10.1039/B810481F10.1039/B810481F ↗
78. 10.18632/oncotarget.47310.18632/oncotarget.473 ↗
79. 10.1038/ng118010.1038/ng1180 ↗
80. 10.1073/pnas.050658010210.1073/pnas.0506580102 ↗
81. 10.1186/1471-2105-10-4810.1186/1471-2105-10-48 ↗
82. 10.1186/s13148-021-01037-110.1186/s13148-021-01037-1 ↗
83. 10.1093/bioinformatics/btq03310.1093/bioinformatics/btq033 ↗
84. Li H. · arXiv:1303.3997v2 [q‐bio.GN] · 2013
85. 10.1093/bioinformatics/btu31410.1093/bioinformatics/btu314 ↗
86. 10.1093/bioinformatics/btv09810.1093/bioinformatics/btv098 ↗
87. 10.1002/0471250953.bi1110s4310.1002/0471250953.bi1110s43 ↗
88. 10.1093/nar/gkq60310.1093/nar/gkq603 ↗
89. 10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S ↗